Skip to main content

Table 4 Number (%) of patients with prior treatment of a biologic agent

From: Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation

  Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Psoriasis Other a Total
N [N missing] 188 [3] 43 [0] 44 [0] 35 [0] 19 [12] 329 [15]
No prior treatment 127 (67.6%) 28 (65.1%) 30 (68.2%) 24 (68.6%) 15 (78.9%) 224 (68.1%)
Unsure of prior treatment 24 (12.8%) 5 (11.6%) 6 (13.6%) 4 (11.4%) 1 (5.3%) 40 (12.2%)
Any prior treatment 37 (19.7%) 10 (23.3%) 8 (18.2%) 7 (20.0%) 3 (15.8%) 65 (19.8%)
   Adalimumab 31 (16.5%) 5 (11.6%) 7 (15.9%) 2 (5.7%) 3 (15.8%) 48 (14.6%)
   Infliximab 7 (3.7%) 4 (9.3%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 12 (3.6%)
   Anakinra 2 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.6%)
   Abatacept 0 (0.0%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.3%)
   Rituximab 3 (1.6%) 1 (2.3%) 1 (2.3%) 0 (0.0%) 0 (0.0%) 5 (1.5%)
   Efalizumab 1 (0.5%) 0 (0.0%) 0 (0.0%) 4 (11.4%) 0 (0.0%) 5 (1.5%)
  1. a Includes patients with juvenile idiopathic arthritis (n = 9, 2.6%), patients responding other or not sure of condition (n = 10, 2.9%) and patients with condition missing (n = 12, 3.5%) to the question 'What condition do you have that is being treated with Enbrel?'